Liraglutide is a first-generation GLP-1 receptor agonist made by Novo Nordisk. It is sold under two brand names: Victoza, approved for type 2 diabetes, and Saxenda, approved for chronic weight management. Both are given as a once-daily subcutaneous injection.
Its main practical difference from newer options such as semaglutide and tirzepatide is dosing frequency: liraglutide has a shorter half-life (roughly 13 hours), so it is injected every day rather than once a week.